New Delhi, India -- (SBWIRE) -- 09/11/2018 -- Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) which increases the risk of bleeding. In this condition, the platelet count of a patients drops down to less than 150 x 103 per ?L. Typically, platelet counts higher than 50 x 109 per L do not lead to clinical problems unless platelet dysfunction co-exists with the low count; rather, they are picked up on a routine complete blood count. A normal platelet count in adults ranges from 150,000 to 450,000 platelets per microliter of blood. A platelet count of less than 150,000 platelets per microliter, indicates the condition of thrombocytopenia. Thrombocytopenia is more prevalent in women than men, with 2.6 cases among women for every case involving a male.

According to the report of DelveInsight "Thrombocytopenia Market Insights, Epidemiology and Market Forecast-2027", among 7MM, the total prevalent cases of Thrombocytopenia in 2016 were found out to be XXXX, out of which Thrombotic Thrombocytopenic Purpura was very rare and accounted for XXXX Cases in 2016 whereas Idiopathic Thrombocytopenic Purpura were relatively common and accounted for XXXX cases in 2016. Around XXXX cases of chronic ITP persisted to chronic refractory ITP in 2016. Chemotherapy induced Thrombocytopenia and Heparin induced Thrombocytopenia cases were XXXX and XXXX respectively in 2016. Among EU5 countries, Germany has the highest prevalent population of Thrombocytopenia, followed by France. Spain accounts for the lowest number of prevalent cases. The incidence of immune thrombocytopenia among adults in the USA is estimated to be XX per 100,000 adults/year and the prevalence rate is XX cases per 100,000. The annual prevalence is estimated at XX per 100,000 among children.

Market Outlook

Thrombocytopenia is one of the most common hematologic disorders, which is the leading cause of morbidity worldwide. The therapeutic market is mainly driven by the adulthood and childhood patient pools with an increase in prevalent cases. Market analysis study carried out for the period of 2016-2027 demonstrates that the Market size of Thrombocytopenia was about USD 1,183 million in 2016 in 7MM. The current Thrombocytopenia market is dominated by approved therapies such as Nplate (Amgen/Kyowa Hakko Kirin), Rhophylac (CSL Behring), Privigen (CSL Behring) etc.

The report covers the descriptive overview of Thrombocytopenia explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Thrombocytopenia market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Thrombocytopenia by reviewing the market drivers and barriers.

Request for sample pages : https://www.delveinsight.com/report-store/thrombocytopenia-market-insight-epidemiology-and-market-forecast

Reasons to buy:

1. The report will help in developing business strategies by understanding trends shaping and driving the Thrombocytopenia market.
2. To understand the future market competition in the Thrombocytopenia market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Thrombocytopenia market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

1. Dova Pharmaceuticals
2. Rigel Pharmaceuticals

And many others……………

Table of contents

1. Key Insights
2. Thrombocytopenia Market Overview at a Glance
3. Disease Background and Overview: Thrombocytopenia
4. Epidemiology and Patient Population
5. UNMET NEEDS
6. MARKETED PRODUCTS
6.1. DRUG 1: OCTAPHARMA USA
6.2. DRUG 2: AMGEN
6.3. DRUG 3: COMPANY 3
6.4. DRUG 4: COMPANY 4
6.5. DRUG 5: COMPANY 5
7. EMERGING THERAPIES
8. FILED & PHASE III DRUGS
8.1. DRUG 1: COMPANY 1
8.2. DRUG 2: COMPANY 2
8.3. DRUG 3: COMPANY 3
8.4. DRUG 4: COMPANY 4
8.5. DRUG 5: COMPANY 5
9. PHASE II DRUGS
9.1. DRUG1: COMPANY 1
9.2. DRUG2: COMPANY 2
9.3. DRUG3: COMPANY 3
9.4. DRUG4: COMPANY 4
9.5. DRUG5: COMPANY 5
10. THROMBOCYTOPENIA: MARKET ANALYSIS
11. THROMBOCYTOPENIA: TOTAL MARKET SIZE IN 7MM
12. MARKET SIZE OF THROMBOCYTOPENIA BY COUNTRY
12.1. United States
12.2. Germany
12.3. France
12.4. Italy
12.5. Spain
12.6. United Kingdom
12.7. Japan
13. MARKET DRIVERS
14. MARKET BARRIERS
15. APPENDIX
15.1. Report Methodology
16. DELVEINSIGHT CAPABILITIES
17. DISCLAIMER

*** For detailed TOC request for sample pages.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.